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Abstract  
Antipsychotic drugs came out in 1950s for the first time, but had severe moving side effects. In the 1980s 
another kind of antipsychotic medication came out, but these too have side effect, metabolic side effects. 
One of the major once is antipsychotic-induced weight gain. Pharmacogenomics has not come as far as 
hoped a decade ago for the purpose of personalized medicine and new methods could be what are needed 
to move the research along.  
This project is designed as a review article and is divided into two parts. First part concerns where 
pharmacogenomics research was in 2015 and the second part covers relatively new methods of 
metabolomics and pharmacometabolomics. Because no pharmacometabolomic study has been conducted 
on antipsychotics, aspirin was used as a reference. A whole new idea has emerged, 
pharmacometabolomics-informed pharmacogenomics, which makes it possible to investigate new 
pathways and takes the core of both areas into one research.  
 
 
 
Antipsykotika kom ud i 1950 for første gang, men havde alvorlige bivirkninger ved ufrivillige bevægelser. I 
1980'erne kom en anden slags antipsykotisk medicin ud, men også disse havde bivirkninger, her 
metaboliske bivirkninger. En af de alvorlige bivirkninger er antipsykotisk-induceret vægtøgning. 
Farmakogenomisk er ikke kommet så langt som håbet for et årti siden med henblik på personlig medicin, og 
derfor kan nye metoder være, hvad der er behov for. 
Dette projekt er udformet som en review artikel og er opdelt i to dele. Første del vedrører, hvor 
farmakogenomisk forskning var i 2015, og den anden del dækker relative nye metoder til forskning i 
metabolomet og farmakometabolomik. Da der endnu ikke er lavet studier i farmakometabolomik for 
antipsykotika, så er aspirin brugt som reference. En helt ny idé er opstået, farmakometabolomisk-
informeret farmakogenomik, hvilket gør det muligt at undersøge nye pathways og benytter kernen i begge 
områder i én forskning. 
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Introduction  
Antipsychotic medication is commonly used in some psychiatric disorders, for example schizophrenia. 
Antipsychotics have two issues, one is poor response to treatment and the other is severe side effects. Only 
about 50 percent of schizophrenic patients respond positively to antipsychotic treatment (Xu et al. 2015) 
and multiple studies show that one of the more serious, but common side effect is antipsychotic-induced 
weight gain (AIWG) (Sørensen 2015; Shams & Müller 2014; De Hert et al. 2009). AIWG can further give 
severe morbidities such as diabetes, cardiovascular disease and metabolic syndrome (sundhed.dk 2015; 
Shams & Müller 2014). Both issues are unfortunate and strategies to pinpoint the potential affected 
patients are an important objective so that the treatment response will be improved and AIWG can be 
avoided. These results will improve personalized medicine in the future.  
Both genetics and the environment play a part in schizophrenia as a disease and in the treatment with 
antipsychotics. Research suggests that schizophrenia is a developmental disorder of the brain and it is an 
inherited disease in which the right environmental factors may trigger the symptoms. It can therefore skip a 
generation if the right environmental factors does not occur (Straszek 2015). AIWG is also thought to have 
genetic factors and therefore the research community has spent the last 10 years trying to find a way in 
pharmacogenomics in which the patients can be screened for the tendency to poor treatment and specific 
side effects.  This would help the medical health professionals, so that they can direct the right medication 
to the right people and thereby avoid the severe side effects all together. The desired outcomes have yet to 
be found (Shams & Müller 2014).  
The lack of results can be because genetics may not be the only answer for the variation in the response to 
treatment with antipsychotic drugs. Other factors might contribute such as the environment, age, sex and 
ethnicity. Hence, the need for new approaches that can help find the effects of these factors and thereby 
complementing the genomic information (Kaddurah-Daouk & Weinshilboum 2014). The relatively new field 
of metabolomics and its more specified area pharmacometabolomics could contribute to personalize the 
treatment with antipsychotics. Pharmacometabolomics determines the metabolic profile of an individual 
who is affected by genetics and environment. Pharmacometabolomics may compliment 
pharmacogenomics by providing biomarkers, that can help define drug response phenotypes (Kaddurah-
Daouk & Weinshilboum 2014).  
The main emphasis of this report is a review article focusing on how pharmacogenomics in AIWG in 2015 
looks like and find out how far the research has come and where metabolomics is in the pursuit of 
personalizing antipsychotic treatment.  
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Problem formulation 
How can metabolomics improve treatment with second generation antipsychotics? 
  
Delimitation 
This project have a few delimits. First of all it the review is about pharmacogenomics and metabolomics 
and thus the transcriptome and proteomics is not included. In this way the review is about the beginning 
with the genes and the end with the metabolites. Second delimitation is all other side effect than 
antipsychotic-induced weight gain is not included. This is because AIWG is a major side effect and has the 
potential to induce the other side effects such as cardiovascular disease, diabetes and metabolic syndrome. 
Third, the various antipsychotic drugs have not been search for individually. Fourth, articles on other 
disorders than schizophrenia have not been included. Fifth delimitation is that all research articles with 
other subjects than humans have not been included.  
 
Method  
This project is a literature study and is written as a review article. The review is based on a systematic 
analysis of scientific literature from three databases: Medline, Web of Knowledge and SCOPUS. The 
keywords used were: schizophrenia, antipsychotics, pharmacogenomics, metabolomics, pharmaco-
metabolomics, weight gain and pharmacometabolomic-induced pharmacogenomics. For the first part of 
the review, the publication time of the search were delimited to 2015. For the second part of the review, all 
articles were looked through, because only little research has been done in this field for antipsychotics. 
That is why aspirin have in this review been used as a reference for pharmacometabolomics. The selection 
process was first an assessment of the headline, then the abstract and finally the conclusion. Did the article 
pass through this selection then the whole article was read.  
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Background  
In the following different aspects are outlined. These aspects are important background knowledge for the 
review article.  
Personalized medicine  
Today medicine is ‘standard of care’ and that means ‘one-size-fits-all’ and that again means ‘trial and error’ 
(McMullan 2015). Most often that is enough but not always and that is why a more personalized appoach 
will help prevent and treat disease (Eckhart et al. 2011; McMullan 2015). Stratification is the closest to 
personalized medicne as it gets right now and it is a way of treating patients. Stratification is basicly 
patients assigned to a subgroup where a certain kind of medication seems to work well (Schleidgen et al. 
2013). Personalized medicine is also referred to as individualized medicine, precision medicine and genomic 
medicine (McMullan 2015). The term personalized medicine will be used prospectively.  
In 2013 Schleidgen and collegues wrote a systematic review about defining the term ‘personalized 
medicine’. They found that the term ‘personalized medicine’ was used for the first time in 1971, but it was 
not until the 1999/2000 that it intensified (Schleidgen et al. 2013). In 2002 there was a growth rate increase 
in puplished articles on personalized medicine of 160 percent and that might be because of the hopes of 
gene-based medicine (Schleidgen et al. 2013) based on the Human Genome Project that successfully 
sequenced a whole genome in April 2003. In the late 1990s the development of pharmacogenetics and 
pharmacogenomics enhanced the development of personalized medicine (Plesni 2015).  
The definition they came up with was: Personalized Medicine seeks to improve stratification and timing of 
health care by utilizing biological information and biomarkers on the level of molecular disease pathways, 
genetics, proteomics as well as metabolomics (Schleidgen et al. 2013). 
The foundation of personalized medicine is biomarkers. Biomarkers are used for diagnosing, preventing and 
treating disease. Information from several areas is taken into account when biomarkers are found; genes, 
proteins and the environment. “Omic” strategies, as profiling technologies, have given a foundation with 
plenty of data to perform unbiased investigation. The challenge now is how to find the information from 
these data and how best to incorporate the information across the different omics; genomics, 
transcriptomics, proteomics, and metabolomics (Eckhart et al. 2011). 
A personalized medicine approach will be able to help maximized response and avoid side effects in 
treatment with antipsychotic drugs (Naumovska et al. 2015; Plesni 2015).  
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Antipsychotics  
Antipsychotic drugs are the most common treatment for the major psychiatric disorders like schizophrenia, 
bipolar mania, and psychotic depression (Seida et al. 2012; Zhang et al. 2015; Xu et al. 2015; Matos et al. 
2015; Brandl et al. 2015; Wang et al. 2015). Antipsychotics came out in the 1950s and are called first 
generation antipsychotics (FGA) or typical antipsychotics. In the 1980s came second-generation 
antipsychotics (SGA) or atypical antipsychotics (Seida et al. 2012).  
Even though antipsychotics help a lot of patients to remission, there is still a large interindividuel variability 
in efficacy and adverse effects (Pouget et al. 2015; Bishop et al. 2015; Brandl et al. 2015; Matos et al. 2015; 
Xu et al. 2015; Zhang et al. 2015). FGA have extrapyramidal symptoms as primary side effect and SGA are 
associated with weight gain, lipid and prolactin elevation, and development of type 2 diabetes (Seida et al. 
2012). In schizophrenic patients up till 30 percent do not respond to the treatment while five to 20 percent 
stop their treatment because of side effects (Pouget et al. 2015). One of the leading side effects there make 
patients stop their treatment is antipsychotic-induced weight gain (Fonseka et al. 2015; Tiwari et al. 2015). 
Weight gain is not just a health risk but for young female patients physical appearance can be a concern too 
(Wang et al. 2015).    
Weight gain is a major concerning side effect for SGA (Pouget et al. 2015; Fonseka et al. 2015). Weight gain 
is caused in 15-72 percent of patients with schizophrenia (Fonseka et al. 2015) and over the treatment 
period 30 percent of patients gain seven percent or more of their initial bodyweight (Pouget et al. 2015). 
Particularly clozapine (CLZ) and olanzapine (OLZ) cause weight gain and metabolic syndrome (Fonseka et al. 
2015; Tiwari et al. 2015). AIWG can increase the risk of developing various other medical conditions like 
obesity, metabolic irregularities, cardiovascular disease, hypertension and premature mortality (Fonseka et 
al. 2015; Wang et al. 2015). Today to find the right treatment is used trial and error and that can take a long 
time (Xu et al. 2015).  
It is important that the benefits get improved and the side effects are reduced. Markers are needed there 
can help clinically and guide the treatment choice (Bishop et al. 2015; Xu et al. 2015; Zhang et al. 2015). 
Pharmacogenomics may be useful for this purpose (Bishop et al. 2015).   
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Sascha Andersen 
 
Pharmacogenomics has been of great interest in the past decade in the attempt to personalize 
antipsychotic treatment, but it has not been yielding the results there where hoped.  Other research areas 
have emerged such as metabolomics and pharmacometabolomics. This review is divided into two parts. 
Part one gives an update on the research in pharmacogenomics for the antipsychotic-induced weight gain 
side effect in 2015. Part two covers the principle of metabolomics in relation to antipsychotics and 
pharmacogenomics. Because the research has not reached antipsychotics in pharmacometabolomics, 
aspirin is then used to outline the field.  
 
Dopaminergic, serotoninergic and glutamatergic 
systems are often the systems there are 
investigated in to find the pathophysiology of the 
major psychiatric disorders, but the problem is 
that they are usually studied separately (Yao & 
Reddy 2005; Cai et al. 2012). The major 
psychiatric disorders like schizophrenia, bipolar 
and major depression are most likely to have 
“multineurotransmitter” pathologies (Yao & 
Reddy 2005; Cai et al. 2012). Antipsychotic drugs 
are the most common treatment for these 
disorders and they came out for the first time in 
the 1950s and then again in the 1980s and are 
called first-generation antipsychotics and second-
generation antipsychotic respectively (Seida et al. 
2012). The issue with second-generation 
antipsychotics is that they have severe side 
effects like antipsychotic-induced weight gain 
(AIWG) (Shams & Müller 2014). So far the 
research community has not yet been able to 
personalize the treatment in this area with 
pharmacogenomics.  
The scope of the present review is antipsychotic 
treatment with focus on AIWG. The review is 
designed to first give an overview of how the 
pharmacogenomics research looked like in 2015 
and demonstrate the point above that the 
research in this area is narrow and not really 
close to any useful results. Lastly another area, 
metabolomics, is described from current research 
to give an idea to the potential the field has to 
personalize antipsychotic treatment in combi-
nation with pharmacogenomics.  
Three databases were used to find the articles 
used in this review: Medline, Web of Knowledge 
and SCOPUS. The search in pharmacogenomics 
was limited to published original articles in 2015. 
For the other areas no time limited was made. 
Keywords used were: schizophrenia, anti-
psychotics, pharmacogenomics, metabolomics, 
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weight gain and pharmacometabolomic-informed 
pharmacogenomics. 
  
Part One – Pharmacogenomics  
Part one is of four different studies concerning: 
The SLC6A4 gene, TSPO, HCRTR2 and cytokines. 
Their results and study limitations are described.  
 
SLC6A4 
Serotonin plays an important role in the control 
of appetite and bodyweight. The SLC6A4 (solute 
carrier family 6 (neurotransmitter transporter), 
member 4) gene encodes a serotonin 
transporter, which can transport serotonin from 
synaptic space back into presynaptic neurons. It 
influences the synaptic serotonin concentrations 
and can terminate the action of serotonin (Wang 
et al. 2015).  
In a study by Wang and colleagues (2015), aimed 
to find susceptible genes for weight gain after 
four weeks of treatment with risperidone in 
Chinese Han patient, they found that there were 
215 patients and 738 SNPs left after exclusion for 
an association analysis. On SLC6A4 they found 
four significant SNPs left with a p-value under 
0.05 after multiple-correction. The most 
significant SNP on SLC6A4 was rs3813034. Wang 
et al. found that the AA carrier gained the most 
significant weight after four weeks of risperidone 
treatment, while the CC carrier gained the least 
amount of weight. The AC carrier was in 
between. Before multiple-correction there were 
other genes with a p-value under 0.05, but they 
did not continue to be significant after multiple-
correction (Wang et al. 2015).  
The SNP rs3813034 is located on the 3-UTR of 
SLC6A4. This SNP is predicted to affect miRNA-
mRNA binding, specifically the binding between 
SLC6A4 and miR2053, miR-569 and miR-571. The 
binding will break between SLC6A4 and miR-2053 
and miR-569 if the A allele change to C allele and 
the binding between SLC6A4 and miR-571 will 
decrease. This makes the SNP rs3813034 
interesting for further functional study on weight 
gain (Wang et al. 2015).  
 
Limitations 
Their main limitations were: they used candidate 
gene approach which is limited because only the 
gene they thought to have an effect can by 
chosen. New genes can therefore not be 
discovered. Confounders in terms of lack of prior 
treatment history were sought to be minimized 
be using weight change in percent (Wang et al. 
2015).  
 
TSPO 
TSPO is a transmembrane protein localized to the 
outer mitochondrial membrane and it is highly 
conserved and ubiquitous. For brain injury TSPO 
acts as a molecular sensor, mediating signaling in 
the brain to control the inflammatory response 
required for injury repair. TSPO binding is 
considered a biomarker for neuroinflammation 
(Pouget et al. 2015).  
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Pouget and coworkers examined 694 patients of 
European ancestry with schizophrenia or 
schizoaffective disorder and found a non-
significant trend for association between weight 
gain and rs6971 equivalent to 1.35 percent of 
baseline weight for each Thr allele a patient 
carried. In the group of 78 patients treated with 
clozapine or olanzapine rs6971 was nominally 
associated with weight gain, but did not stay 
significant after multiple testing corrections. No 
association between TSPO rs6971 and weight 
gain was found in another sample consistent of 
300 patients (Pouget et al. 2015). However in a 
third sample of 184 patients, rs6971 did show an 
association with AIWG.  
The possibility of genetic interaction between 
TSPO rs6971 and ANT1 also known as SLC25A4 
rs10024068 and rs7660552 were examined. 
Among the 694 patients 109 were treated with 
clozapine, olanzapine, risperidone or quetiapine. 
In this subset rs10024068 exhibited a significant 
interaction in association with weight gain with 
rs6971. rs10024068 had no association with 
AIWG if the patients did not carry at least one 
copy of the Thr allele (Pouget et al. 2015). 
 
Limitations  
Their limitations were: across the TSPO gene 
there was less than complete coverage of 
common variations. They had a small sample size 
and did not correct for testing of multiple 
phenotypes (Pouget et al. 2015). 
 
HCRTR2  
Tiwari et al. (2015) investigated the impact of 
genetic variation in the orexin/hypocretin system 
genes on AIWG. The orexin system comprises the 
orexin gene coding for a protein which is cleaved 
into two polypeptides, orexin A (OXA) and orexin 
B (OXB). The biological action of the orexin 
peptides is mediated two receptors: orexin 
receptor 1 (OX1R or HCRTR1) and orexin receptor 
2 (OX2R or HCRTR2). The orexin receptors are 
expressed in multiple regions in the brain (Tiwari 
et al. 2015).  
It looks like the orexin system genes plays a 
potential role in AIWG, because it has been 
shown that antipsychotic drugs associated with 
weight gain increase neuronal activity in orexin 
neurons compared to antipsychotic medication 
that does not have this association with weight 
gain (Tiwari et al. 2015).  
Tiwari and colleagues examined 218 patients of 
different ancestry with schizophrenia or 
schizoaffective disorder and did not find any 
association between SNPs and AIWG. They 
continued therefore there analysis with 151 
patients of European ancestry. There Tiwari and 
coworkers found nominal genotypic association 
of rs4142972, rs3134701 and rs4467775 all with a 
p-value under 0.05 in HCRTR2 with weight gain 
(Tiwari et al. 2015). Out of the 151 patients of 
European ancestry 86 patients were treated with 
clozapine or olanzapine. Because these two 
antipsychotics have the highest risk of weight 
gain and their pharmacology is alike Tiwari et al. 
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carried out an analysis of this group of patients. 
They found nominal genotypic association of 
rs2653350, rs12662510 and rs6922310 in 
addition to the above three SNPs. Patients with 
risk genotypes gained more weight than the non-
risk genotype, for example gained the AA 
genotype of rs6922310 and the A-allele carriers 
for rs4142972 2.6 and 2.8kg more weight 
respectively (Tiwari et al. 2015).  
They also carried out a haplotype analysis of the 
patients treated with clozapine or olanzapine and 
that showed that after correcting for multiple 
testing, haplotypes of the HCRTR2 SNPs 
rs12111375, rs4142972 and rs6922310 were 
significantly associated with AIWG. The ones who 
gained less weight were carriers of the T-G-G 
haplotype and the carriers of the T-A-A haplotype 
gained more weight (Tiwari et al. 2015). 
In an earlier study by Tiwari and colleagues they 
found the SNPs rs806378 in CNR1 and rs16147 in 
NPY to be associated with AIWG. Therefore an 
exploratory gene–gene interaction analysis was 
performed in the group of patients treated with 
clozapine or olanzapine of European ancestry. 
This was between rs4142972 in HCRTR2 with 
rs16147 in NPY and rs806378 in CNR1. The 
patients who gained the least amount of weight 
were carriers of the TT genotype at rs16147, the 
CC genotype of rs806378 and the GG genotype at 
rs4142972. This was also done for the rs6922310 
SNP in HCRTR2 but they did not find a significant 
interaction (Tiwari et al. 2015). 
These observations imply that HCRTR2 gene is 
probably to play a role in AIWG development 
(Tiwari et al. 2015). 
 
Limitations  
Their limitations were: a small sample size, 
because they adjusted for ethnicity and type of 
antipsychotic medication. There was not done an 
ancestry test, the information was provided by 
the patients then selves. None of the test 
observations could meet the statistical threshold 
of P < 0.05. The genetic polymorphisms were not 
tested for association with AIWG in the orexin 
gene (Tiwari et al. 2015). 
 
Cytokines  
An association between variations in 
inflammatory genes and weight change during 
treatment with antipsychotics has been shown.  
Cytokine involvement in AIWG has gotten some 
attention because studies have shown 
antipsychotic induced alterations in cytokine 
levels simultaneously with changes in body 
weight. In certain regions in the brain 
antipsychotic drugs reduce levels of brain-derived 
neurotrophic factor (BDNF) (Fonseka et al. 2015).  
Fonseka and colleagues (2015) observed four 
genotypic associations in their total sample of 
188 chronic schizophrenia or schizoaffective 
disorder patients treated with different 
antipsychotic drugs. Those associations were IL-
1b rs4849127, rs16944, and rs1143634, and 
BDNF Val66Met with weight change in percent. 
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Carriers of the A allele gained around four 
percent more weight than individuals 
homozygous for the G allele for IL-1b rs4849127. 
Patients with the heterozygous GA genotype 
gained also approximately four percent more 
weight than patients with either homozygous 
genotype AA or GG. For IL-1b rs1143634 the once 
there were homozygous for the A allele gained 
less weight than G allele carriers around six 
percent and carriers of the Met allele for BDNF 
Val66Met gained less weight than patients 
homozygous for the Val allele, about four 
percent. If the sample were separated into 
European ancestry and African ancestry the 
pattern of findings are alike. Significant among 
patients of European ancestry especially IL-1b 
rs16944, IL-1b rs1143634 and BDNF Val66Met 
while for patients of African ancestry IL-1b 
rs4849127 and IL-1b rs16944 were significant 
(Fonseka et al. 2015).  
Consistent with the literature, clozapine and 
olanzapine had the highest weight gain from 
baseline compared to haloperidol or risperidone. 
For patients of European ancestry on clozapine or 
olanzapine only BDNF Val66Met stayed 
significant and for patients of African ancestry IL-
1b rs16944 continued to be significant.  
Fonseka et al. also investigated epistatic effects, 
for an association with weight change in percent 
from baseline, between variant sites across each 
of IL-1b, IL-2, and IL-6 and the BDNF Val66Met 
locus (Fonseka et al. 2015). There was observed 
interaction between IL-1b rs13032029 and BDNF 
Val66Met in patients on clozapine or olanzapine 
of European ancestry. Identified as low risk for 
AIWG was the TT genotype carriers at IL-1b 
rs13032029 and Val/Met genotype carriers at 
BDNF Val66Met compared to individuals with any 
other genotypic combination at these loci. 
Another interaction was observed between IL-6 
rs2069837 and BDNF Val66-Met. Identified as 
high risk for AIWG were carriers of the AA 
genotype at IL-6 rs2069837 and the Val/Val 
genotype at BDNF Val66Met (Fonseka et al. 
2015). For patients of African ancestry the 
observed interaction was between IL-1b rs16944 
and BDNF Val66-Met. Identified as high risk for 
AIWG were the GA genotype carriers at IL-1b 
rs16944 and the carriers of the Val/Val genotype 
at BDNF Val66Met.  
For the patients of European ancestry IL-1b SNPs 
rs16944 and rs1143634 were significantly 
involved in mediating the weight gain and 
rs1143634 remained significant after correcting 
for multiple comparisons. For patients of African 
ancestry IL-1b SNPs rs16944 and rs4849127 were 
associated with AIWG, but the discoveries did not 
persist to be significant after correction (Fonseka 
et al. 2015). 
 
Limitations  
Their limitations were: their small sample size. 
Confounders for patients’ antipsychotic dose, 
cigarette smoking, cannabis use and diet and the 
effect of these cannot be ruled out (Fonseka et al. 
2015). 
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Part Two – Metabolomics 
Metabolomics is the study of metabolism at the 
global or ‘-omics’ level. It comprises systematic 
study of the metabolome, the complete range of 
small molecules present in cells, tissues or 
organisms which reflect the metabolic processes. 
These small molecules are referred to as 
metabolites and includes antioxidants, amino 
acids, catecholamines, vitamins, lipids, and 
nucleotides (Yao & Reddy 2005; Kaddurah-Daouk 
et al. 2007). This research field is still relatively 
new and it can influence the medical practice at 
many levels. An individual’s metabolic state 
reflects both the genome and the environment 
and the environment includes drug influence 
(Kaddurah-Daouk et al. 2007). By investigating 
the global disturbances in biochemical pathways 
in complex diseases such as schizophrenia and 
treatment with antipsychotics a deeper 
understanding will emerge and provide valuable 
insights about mechanisms of disease, drug 
effects and biomarkers (Kaddurah-Daouk et al. 
2007). Analytical platforms and informatics tools 
have already been developed that are making it 
possible to begin the process of defining 
signatures for disease and pathways (Kaddurah-
Daouk et al. 2007), but there is yet to be 
researched in the area of AIWG. For this review 
only one research article was found there used 
human patients.  
 
Lipidomics  
Lipidomics is a specialized metabolomics platform 
and is used by Kaddurah-Daouk et al. (2007) to 
map global lipid changes in schizophrenia before 
and after treatment with three different 
antipsychotics. 
Kaddurah-Daouk and colleagues showed that 
phosphatidylcholine, phosphatidylethanolamine 
and triacylglycerol were increased in 14 patients 
with schizophrenia, schizophreniform disorder or 
schizoaffective disorder treated with olanzapine 
and free fatty acids were decreased using heat 
map. Phosphatidylcholine and phosphatidyl-
ethanolamine did also increase in the nine 
patients treated with risperidone. It was only 
phosphatidylethanolamine that increased in the 4 
patients treated with aripiprazole. Thus only one 
metabolite, PE22:5n6, was significantly changed 
by all three antipsychotic drugs. There were 
changes with all metabolites after treatment with 
olanzapine and there were almost none with 
aripiprazole (Kaddurah-Daouk et al. 2007).   
Both olanzapine and risperidone had effect on 
free fatty acids and triacylglycerol, but 
aripiprazole did not and this suggests that these 
antipsychotic drugs are associated with the 
metabolic side effects. A larger future study with 
focus on identifying prognostic markers specific 
for each drug could potentially contribute to 
better optimization of treatment for each patient 
and better prognostic prediction of outcomes 
(Kaddurah-Daouk et al. 2007). Metabolomics is a 
promising tool for finding markers of response 
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and nonresponse, which is pharmaco-
metabolomics (Kaddurah-Daouk et al. 2007). 
 
Pharmacometabolomics  
Pharmacometabolomics is a refinement of 
metabolomics. It is a new field and it is using the 
tools from metabolomics to identify the 
biochemical basis for variation in response to 
treatment and the mechanisms of action for 
drugs. The above mentioned metabolites are the 
final outcome of the entire chain of regulatory 
changes that occur in response to treatment and 
are measured in body fluids such as blood or 
urine (Ellero-Simatos et al. 2014). To the best of 
my knowledge no pharmacometabolomics study 
has yet been performed on antipsychotic 
treatment. Therefore this review will use a 
research article of aspirin as an example of the 
method. 
 
Ellero-Simatos and coworkers (2014) applied 
pharmacometabolomics to investigate the 
variation of treatment to aspirin. To identify the 
primary sources of variation in serum metabolic 
profiles of subjects they used a quantitative mass 
spectrometry based metabolomics platform 
targeted to the measurement of metabolites 
containing an amine functional group (Ellero-
Simatos et al. 2014). This gave them 19 individual 
metabolites there were significantly different 
post- compared to pre-aspirin exposure (Ellero-
Simatos et al. 2014).  
Their conclusion was that they successfully used 
pharmacometabolomics in establishing new 
metabolic signature of drug exposure and that 
certain metabolite levels may contribute to 
predict aspirin response (Ellero-Simatos et al. 
2014).  
 
Pharmacometabolomics-Informed 
Pharmacogenomics  
This review have now covered 
pharmacogenomics, metabolomics and 
pharmacometabolomics and separately they 
work as they are meant to do, but what if they 
are combined? They technology of 
pharmacometabolomics combined with the 
methodologies pharmacogenomics is called 
pharmaco-metabolomics-informed pharmaco-
genomics (Yerges-Armstrong et al. 2013). 
Yerges-Armstrong et al. (2013) used this 
approach to examine novel mechanisms of 
aspirin resistance. To characterize the 
metabolomic signature of aspirin exposure and 
find important pathways affected, they first made 
a metabolomics profiling of serum samples 
before and after low-dose aspirin treatment using 
an untargeted gas-chromatography (GC)-MS-
based metabolomics platform. That information 
was used to complete a focused genetic 
association analyses (Yerges-Armstrong et al. 
2013). The metabolites from the GC-MS of all 
participants were used in a multi-level principal 
component analysis (ML-PCA) to examine the 
major sources of variation in serum metabolic 
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profiles. Pathway enrichment analysis was 
performed using other metabolites to find novel 
pathways associated with aspirin exposure.  
The most significant pathway, here the purine 
pathway, was used to find candidate genes for 
further analysis (Yerges-Armstrong et al. 2013). 
Untargeted metabolic profiling may be used to 
detect new metabolic pathways involved in a 
drug’s mechanism of action (Yerges-Armstrong et 
al. 2013) for example antipsychotic drugs. Yerges-
Armstrong and colleagues (2013) experienced 
that this untargeted approach allowed them to 
quickly hone in on the purine pathway and then 
inform their genomic inquiries and thereby 
generate repeatable results (Yerges-Armstrong et 
al. 2013). 
Pharmacogenomics have shown large results for 
other drugs during the genome-wide association 
era for identifying underlying genetic variation, 
but for aspirin there have not been the major 
success (Yerges-Armstrong et al. 2013) and the 
same is true for antipsychotics.  
 
Conclusions and future challenges  
The four independent studies of pharmaco-
genomics are the latest published and they each 
researched their own area. It is difficult to reach 
something useful when all the studies are with 
different ancestries and different antipsychotic 
drugs.  Even though research in pharmaco-
genomics in antipsychotics has been going on for 
over a decade there is still no reliable results. 
Larger studies are needed.  
Metabolomics and pharmacometabolomics are 
relatively new research fields and have therefore 
not yet shown results. Future pharmaco-
metabolomics studies could consider using 
targeted or untargeted mass spectrometry for 
identifying the metabolic profile of antipsychotic 
on AIWG. This should especially be for clozapine 
and/or olanzapine, because they are high-risk 
medications for metabolic side effects, but also 
risperidone with medium-risk should be included.  
It might be reasonable to use the pharmaco-
metabolomics-informed pharmacogenomics 
approach for antipsychotic treatment in 
schizophrenia as this disorder is both genetic and 
environmental and the treatment is too. It could 
provide new knowledge and new pathways there 
has not been though of yet.  
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Final remarks 
This section will be used to put my work and thoughts into perspective. 
Right now there is a lot of research on pharmacogenomics in the databases, but it seems like everyone 
have their own thought to what is the cause for antipsychotic-induced weight gain. I have here tried to 
show that trend by only including the four papers published in 2015. Beside the different areas of research 
all the basics are different too. These publications have small subject groups, they have different 
ethnicities, the use different medications and some uses naïve patients and others use chronic patients. All 
these things make it difficult to compare results and discover a pattern. Based on this a new approach 
would not hurt. The new “-omic”, metabolomics have potentials and especially pharmacometabolomics, 
but no one have yet published a study in this field for antipsychotics. Metabolomics alone will not work as 
personalized medicine, because they can be unstable, but together with pharmacogenomics as in 
pharmacometabolomics-informed pharmacogenomics there might be a future.  
I will conclude that this could improve treatment for second-generation antipsychotics and thereby also 
take personalized medicine a further.  
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